无进展生存作为骨髓瘤临床试验的替代终点:一个不断变化的范式
Charlotte Pawlyn1,2, Fredrik H Schjesvold3,4, David A Cairns5
1The Institute of Cancer Research, London, UK. charlotte.pawlyn@icr.ac.uk.
Blood cancer journal
|August 12, 2024
概括
整体存活率 (OS) 是多发性骨髓瘤试验的黄金标准. 然而,无进展生存率 (PFS) 和最小残留疾病 (MRD) 越来越多地被用作更快批准药物的替代终点.
科学领域:
- 血液学 血液学 血液学
- 临床试验 临床试验
- 药物开发 药物开发
背景情况:
- 总体存活率 (OS) 是评估新多发性骨髓瘤治疗方法在第三阶段试验中的黄金标准.
- 改善的患者结果在使用OS作为及时药物批准的主要终点时提出了挑战.
- 替代终点如无进展生存率 (PFS) 和治疗反应被监管机构 (FDA,EMA) 用来证明临床益处.
研究的目的:
- 审查PFS作为替代终点需要在多发性骨髓瘤中仔细解释的情况.
- 探索设计研究的策略,以考虑PFS和OS之间的潜在不一致.
- 讨论子组分析在识别新型多发性骨髓瘤病原体的目标人群中的有用性.
主要方法:
- 文献综述侧重于多发性骨髓瘤临床试验中的代用终点.
- 对监管批准途径和终点利用 (FDA,EMA) 的分析.
- 讨论试验设计和子组分析的统计考虑.
主要成果:
- 无进展生存率 (PFS) 和最小残留疾病 (MRD) 越来越多地被FDA视为加速批准的终点.
- 需要仔细解释PFS,特别是在特定的患者亚组中,因为可能与OS不一致.
- 包括非预先规定的子组分析,可以帮助确定从新疗法中获益最多的患者群体.
结论:
- 虽然OS仍然是黄金标准,但像PFS和MRD这样的替代终点对于加速新型多发性髓瘤治疗的批准至关重要.
- 试验设计必须考虑潜在的PFS-OS不一致性和子组分析的作用,以确保患者的益处.
- 优化终点选择和试验设计对于在多发性骨髓瘤中有效开发药物至关重要.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.2K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.8K
相关概念视频
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:24Kaplan-Meier Approach
115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
01:20Comparing the Survival Analysis of Two or More Groups
166
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
166
01:20Actuarial Approach
69
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
69